A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
Status:
Terminated
Trial end date:
2019-10-25
Target enrollment:
Participant gender:
Summary
This is a single arm, open-label phase Ib study of combining eribulin mesylate with avelumab.
The initial 9-12 patients (MTD cohort) will be enrolled to determine safety of avelumab in
combination with eribulin mesylate. Upon determination of maximum tolerated dose (MTD), 12
additional patients will be enrolled in an expansion cohort (efficacy cohort) to determine
ORR at 6 months.
Phase:
Phase 1
Details
Lead Sponsor:
Monika Joshi, MD
Collaborators:
Big Ten Cancer Research Consortium Eisai Inc. Pfizer